Trial Profile
Open Label, Prospective, Exploratory Study to Investigate the Effect of Inhaled CHF5993 pMDI on Central and Peripheral Airway Dimensions in COPD Patients by Functional Respiratory Imaging
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Beclometasone/formoterol/glycopyrrolate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms FRI
- Sponsors Chiesi Farmaceutici
- 21 Oct 2020 Primary endpoint (Specific image-based airway resistance (siRaw)) has been met, as per Results presented at the CHEST Annual Meeting 2020 by Annual Meeting of the American College of Chest Physicians
- 21 Oct 2020 Primary endpoint (Specific image-based airway volumes (siVaw)) has been met, as per Results presented at the CHEST Annual Meeting 2020 by Annual Meeting of the American College of Chest Physicians
- 21 Oct 2020 Results presented at the CHEST Annual Meeting 2020 by Annual Meeting of the American College of Chest Physicians